Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Rochester Center for Behavioral Medicine
With
Shire
The purpose of this study is to determine whether guanfacine hydrochloride used as an adjunct therapy (to subjects' current stimulant medication) would bring about a statistically significant improvement in AD/HD symptoms.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and females (non pregnant) ages 18-65
Current diagnosis of ADHD and have met the DSM-IV-TR criteria for ADHD
Currently taking an adequate dose stimulant to treat their ADHD (with a sub-optimal response). A suboptimal response is determined by a baseline score of 28 or greater on the ADHD-RS or a CGI score of 4 or greater.
Subjects must be of normal intelligence
English speaking
Able to swallow pills.
You may not be if
Non pregnant or lactating females
Severe Axis I and Axis II disorders
Suicidal
Tourette's
Heart disease or any other serious chronic or acute unstable medical conditions/illnesses that would compromise participation or likely lead to hospitalization during the duration of the study.
A known history or presence of cardiovascular, hepatic, renal, respiratory, or hematologic abnormalities, narrow angle glaucoma, or any other unstable medical or psychiatric conditions (as judged by the primary investigator)
A current or recent history (within the past 6 months) of suspected substance abuse and/or drug dependence as defined by DSM-IV-TR criteria
Healthy weight (not under or over as judged by investigator)
No immediate family member of the investigator or research staff No involvement in a research study in the last 30 days.